New Studies on Bacterial Biofilm May Open Door to Treating Sinusitis
Emeryville, CA-based NovaBay Pharmaceuticals has been investigating ways of eliminating the biofilms created by various types of bacteria. Its chief weapon in this battle is the company’s lead compound, known as NVC-422. A member of a non-antibiotic, anti-infective class of substances called Aganocide compounds, NVC-422 has been shown to exhibit efficacy against biofilms in a series of clinical studies.A biofilm is a thin layer of microorganisms, such as bacteria, that can form on a wide variety of materials, including human tissue. When a biofilm forms on an infection, treatment